4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00

TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur

TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our

10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

SD - Accelerate Diagnostics, Inc (0000727207) (Filer)

TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay.  This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips, President and CEO of Accel

TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA  System (MBT-CA System) and MBT-CA Sepsityper® software extension.

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter ended June 30, 2024. "During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVETM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Additionally, we were able to raise an additional $15 million with certain existing noteholders, whic

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average. It is estimated by the World Health Organization, Sepsis affects an estimated 49 million1 people globally each y

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to review 2024 second quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 9884567. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call

TUCSON, Ariz., May 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024. "During the quarter we installed our first pre-clinical trial site demonstrating our ability to successfully ship, install, train and run the Accelerate Wave™ system with Gram-Negative Positive Blood Culture samples in a clinical microbiology lab," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc.  "We continue to target starting our clinical trial towards the end of the second q

TUCSON, Ariz., May 2, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review 2024 first quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 2853328. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call wi

TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023. "In 2023, we made significant progress with the development of our next-generation rapid Antibiotic Susceptibility Testing system, Accelerate Wave™. We continue to advance this important development program and believe that we remain on plan to begin our clinical trials in the second quarter of 2024," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc.  "In addition, we continu

TUCSON, Ariz., March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 7172610. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A re

SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13G/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13G/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. Genelux (NASDAQ:GNLX) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million. Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million. Bionomics (NASDAQ:BNOX) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million. Xylo Technologies (NASDAQ:XYLO) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million. Accelerate Diagnostics (NASDAQ

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.72) by 22.22 percent. This is a 48.54 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $2.921 million which missed the analyst consensus estimate of $3.000 million by 2.63 percent. This is a 3.88 percent increase over sales of $2.812 million the same period last year.

Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:AXDX) with a Hold and lowers the price target from $2 to $1.

Accelerate Diagnostics (NASDAQ:AXDX) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Accelerate Diagnostics missed estimated earnings by -44.0%, reporting an EPS of $-0.89 versus an estimate of $-0.62. Revenue was up $55 thousand from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.11 which was followed by a 3.0% drop in the share price the next day. Here's a look at Accelerate Diagnostics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -1.07 -1.40 -1.4 -1.5 EPS Actual -1.18 -1.31 -1.7 -1.5 Revenue Estimate 3.53M 3

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.62) by 43.55 percent. This is a 493.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $3.03 million which missed the analyst consensus estimate of $3.45 million by 12.26 percent. This is a 1.85 percent increase over sales of $2.97 million the same period last year.

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. • Shimmick (NASDAQ:SHIM) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million. • MSC Industrial Direct Co (NYSE:MSM) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million. • Walgreens Boots Alliance (NASDAQ:WBA) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion. • Data Storage (NASDAQ:DTST) is projected to report earnings for its fourth quarter. • Affimed (NASDAQ:AFMD) is likely to report quarterly loss at $1.68 per shar

Accelerate Diagnostics (NASDAQ:AXDX) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement. Analysts estimate that Accelerate Diagnostics will report an earnings per share (EPS) of $-0.62. Accelerate Diagnostics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.11, which was fo

Accelerate Diagnostics's (NYSE:AXDX) short percent of float has fallen 26.07% since its last report. The company recently reported that it has 448 thousand shares sold short, which is 2.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 24.74 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Sho

Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $2.1 million. NuCana (NASDAQ:NCNA) stock rose 10.0% to $0.33. The market value of their outstanding shares is at $17.4 million. CNS Pharma (NASDAQ:CNSP) stock rose 7.39% to $0.25. The company's market cap stands at $1.5 million. OneMedNet (NASDAQ:ONMD) stock moved upwards by 6.66% to $1.6. The company's market cap stands at $51.6 million. Galecto (NASDAQ:GLTO) stock moved upwards by 5.04% to $0.67. The market value of their outstanding shares is at $18.1 million. Accelerate Diagnostics (NASDAQ:AXDX) shares moved upwards by 5.0% t